Osteoporosis is a bone disease which robs the bones with its minerals and results to potential fractures, especially in women. Because this bone disease is prevalent in women, many of them undergo bone density tests while young to determine the early risk of osteoporosis, says a popular online health blog. This event may result to over-use of Fosamax, orthopedic experts believe. Long-term use of this drug may potentially lead to strange incidences of thighbone fractures.
Those young people who are found to be at risk of bone diseases, such as osteoporosis and osteopenia, are advised to incorporate a diet rich in calcium and vitamin D, and perform weight-bearing exercises.
Fosamax Injury Lawsuit Center
Monday, January 14, 2013
Wednesday, December 5, 2012
Rottenstein Law Group Heeds Fosamax MDL Court’s Order Designed to Weed Out Bad Cases
The Rottenstein Law Group, which represents clients with claims stemming
from the severe side effects of the drug Fosamax, is taking all
necessary measures to comply with the latest order of the federal
Fosamax MDL court.
By order filed November 20, 2012, Judge
Keenan is requiring each claimant whose federal lawsuit is part of the
Fosamax MDL but who has not alleged that he or she experienced
osteonecrosis of the jaw (ONJ) or osteomyellitis (as a result of having
taken Fosamax) to produce certain information and documentation to
identify specifically the alleged injuries suffered and to substantiate,
with expert testimony, to a “reasonable degree of medical certainty”
the claim that the injuries were caused by Fosamax.
For more information read more on: Rottenstein Law Group Heeds Fosamax MDL Court’s Order Designed to Weed Out Bad Cases
Thursday, October 25, 2012
Treating Cancer through Various Bisphosphonates
Bisphosphonates are a group of antiresorptive drugs used to inhibit accelerated loss of bone mass, paving for lowered fractural risk
in the afflicted, and possibly avoiding the occurrence of the
deficiency for those who may be at risk, according to medical journals.
They are often given to osteoporotic patients and are also sometimes
prescribed to people with osteopenia, an osteoporosis precursor, who may
have been recognized with multiple risk factors. However, as they have
been proven effective in minimizing the fractural risk in users, Fosamax
and other similar drugs have also been associated with a string of
adverse events, which in some instances, have paved the way for a series
of lawsuits.
Visit http://www.fosamaxinjurylawsuitcenter.com for
additional related information involving Fosamax and its related side
effects.Bisphosphonates are also utilized as pain relief in patients with
bone metastasis (cancer that begins in an organ, such as the lungs,
breast, or prostate, and then spreads to bone). Several studies also
reveal that bisphosphonates may possibly prevent metastatic malignant
diseases from causing bony complications and may even improve quality of
life of people enduring myeloma with bone lesions.
Although they may either be used through the mouth or used as an
intravenous drug, most cancer experts utilize the route of intravenous
administration as it is given through a short monthly infusion and has
not been linked to side effects
that most oral bisphosphonates have been reported to cause including
gastrointestinal problems. Some of the most commonly utilized
bisphosphonates for bone metastases include pamidronate (Aredia), and
zolendronic acid (Zometa).
Both manufactured and sold by pharmaceutical company Novartis, Aredia
and Zometa are examples of bisphosphonates administered intravenously
often used as treatment to hypercalcemia of malignancy (treat high
levels of calcium in the blood related to cancer), myeloma, secondary
breast and prostate cancer, as well as Paget’s disease of the bone.
Fosamax, also available by its generic name alendronate, is an
example of a bisphosphonate taken orally, manufactured and widely
distributed by one of the country’s pharmaceutical leader, Merck &
Co. While it is administered differently from Aredia and Zometa, it is
also given to relieve bone pain in people suffering from metastatic bone cancer, multiple myeloma, and Paget’s disease of the bone.
Alongside the benefits that come with these medications are side
effects that may range from mild to severe which may aggravate or
improve during the treatment, according to medical experts. Experts
recommend that patients take utmost precaution to possibly minimize
their risk of experiencing these side effects and added health problems.
Sources:
drugs.com/mtm/aredia.html
cancerhelp.cancerresearchuk.org/about-cancer/treatment/cancer-drugs/disodium-pamidronate
cancerhelp.cancerresearchuk.org/about-cancer/treatment/cancer-drugs/zoledronic-acid
www.medicinenet.com/alendronate/article.htm
oncolink.org/types/article.cfm?c=1&s=89&ss=871&id=9629&CFID=54367541&CFTOKEN=94903688
orthoinfo.aaos.org/topic.cfm?topic=a00093
drugs.com/mtm/aredia.html
cancerhelp.cancerresearchuk.org/about-cancer/treatment/cancer-drugs/disodium-pamidronate
cancerhelp.cancerresearchuk.org/about-cancer/treatment/cancer-drugs/zoledronic-acid
www.medicinenet.com/alendronate/article.htm
oncolink.org/types/article.cfm?c=1&s=89&ss=871&id=9629&CFID=54367541&CFTOKEN=94903688
orthoinfo.aaos.org/topic.cfm?topic=a00093
Tuesday, October 16, 2012
Japanese Medical Product Manufacturer Pioneers Oral Bisphosphonate Jelly
Many orthopedic experts and pharmaceutical specialists believe that bisphosphonates, a medicine class that involves Merck’s Fosamax, is a profitable venture even though several side effects are being allegedly linked to them. In this case, a pharmaceutical company in Japan, Teijin Pharma Ltd., has published a press statement announcing government approval of its 35mg Bonalon Jelly on August 16, 2012. The company affirms that the pharmaceutical formulation is an improved generic of alendronate medicine compared with the 5mg tablet of Fosamax brand.

Teijin stated that a decade of medical study has indicated how alendronate came to be safer based on a few months studies conducted in Japan and China. Both studies have reflected controversial allegations of adverse effects caused by the prescription.
Patients having orthopedic problems should not assume from the affirmation announcement on the recent approval of similar Fosamax generic. It is strongly suggested that they ask for a doctor’s referral regarding any advice of dosage updates. To know more about these issues, read Japanese Pharmaceutical Company Creates First Oral Jelly Bisphosphonate.
Subscribe to:
Posts (Atom)